An interventional study of Biospecimen Collection and Genetic Counseling in BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome, Breast Ductal Carcinoma In Situ and Hematopoietic and Lymphoid System Neoplasm, sponsored by OHSU Knight Cancer Institute. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by OHSU Knight Cancer Institute · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Hereditary Breast and Ovarian Cancer Syndrome · United States.
Among the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States, this one has the largest planned enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2020, is one of 17 with no phase, and was the 26th registered.
62 studies on the registry are indexed under Hereditary Breast and Ovarian Cancer Syndrome; 13 are open to participants now.
Browse Hereditary Breast and Ovarian Cancer Syndrome studies →7 of the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 35+ · Women only
Georgetown University · Sites in United States
Ages 18–74 · Women only
St. Jude Children's Research Hospital · Sites in United States
University of Kansas Medical Center · Sites in United States
Healthy volunteers
Northwestern University · Sites in United States
Ages 18–80 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Hereditary Breast and Ovarian Cancer Syndrome studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 27,500 is above the median of 150 across 43 interventional studies indexed under Hereditary Breast and Ovarian Cancer Syndrome.
Median enrollment 157 across the 23 interventional studies, 440 across the 12 observational. Of the 24 that completed or were terminated, 4 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 35 have an industry lead sponsor. The 10 most frequent:
OHSU Knight Cancer Institute is the lead sponsor of 243 studies on the registry; 42 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 15 (56%) have results posted.
OHSU Knight Cancer Institute has 1 study filed under Hereditary Breast and Ovarian Cancer Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02302742University of Kansas Medical CenterTriple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry | 2026-12 |
| NCT06892275Georgetown UniversityThe FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI | 2027-06 |
| NCT05677048M.D. Anderson Cancer CenterFeasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial examines approaches to identify and care for individuals with inherited cancer syndrome. The purpose of this study is to offer no cost genetic testing to the general public. Researchers hope to learn the value of providing broad, public-wide testing for high risk cancer types (like hereditary breast and ovarian cancer or Lynch syndromes) instead of only testing people whose families are known to be high risk.
PRIMARY OBJECTIVE:
I. Evaluate the effectiveness and sustainability of heritable cancer syndrome testing in two proposed screening populations compared to current guidelines.
SECONDARY OBJECTIVES:
I. Measure adherence to current guidelines for screening and prophylactic intervention of Cohorts B and C compared to Cohort A to show non-inferiority.
II. Measure the efficiency of cascade testing (defined as the ratio of family members screened over total possible) for Cohorts B and C compared to Cohort A to show non-inferiority.
III. Determine the costs and effectiveness, specifically quality adjusted life years (QALYs) associated with genetic screening models based on Cohorts B and C to estimate incremental cost-effectiveness ratio (ICER) and show that the costs per QALY are below the acceptable cost effectiveness threshold.
OUTLINE:
Patients undergo collection of saliva samples for genetic testing. If genetic test is positive, patients receive genetic counseling. Patients also complete a survey about cancer prevention, screening, and treatment.
Inclusion Criteria:
Patients undergo collection of saliva samples for genetic testing. If genetic test is positive, patients receive genetic counseling.
Procedure: Biospecimen Collection · Other: Genetic Counseling · Other: Genetic Testing · Other: Survey Administration
Undergo collection of saliva sample
Also known as: Biological Sample Collection
Receive genetic counseling if testing results are positive
Undergo genetic testing
Also known as: genetic analysis, Genetic Examination, Genetic Test
Complete a survey
Effectiveness and sustainability of heritable cancer syndrome testing in the two novel testing populations
Determine the costs and effectiveness, specifically Quality Adjusted Life Years (QALYs) associated with genetic screening models based on Cohorts B and C to estimate incremental cost-effectiveness ratio (ICER) and show that the costs per QALY are below the acceptable cost effectiveness threshold.
Time frame: Up to 5 years
Adherence to standard of care for hereditary breast and ovarian cancer (HBOC) and Lynch syndromes
For Lynch syndrome we identify compliance as colonoscopy in past two years and bilateral salpingo-oophorectomy (BSO ) after child-bearing age. For HBOC, compliance is defined as breast imaging in past year or risk reducing surgery at any point in women.
Time frame: Up to 5 years
Merged risk reduction strategies of bilateral salpingo-oophorectomy (BSO) or bilateral mastectomy and imaging
The merged risk reduction strategies of BSO or bilateral mastectomy and the imaging are treated as evidence of risk reducing behavior.
Time frame: Up to 5 years
Cascade screening rate among Lynch or HBOC positive carriers
Will conduct negative binomial regression model and non-inferiority will be determined by rate ratio and its 95% confidence interval (CI).
Time frame: Up to 5 years
Plan to share: Yes — Data and samples collected under this protocol will be stored indefinitely in this study's repository for future research use. Participants must agree to future research use of their samples/data to participate in HOP. Data/samples from participants who identify as American Indian/Alaska Native will be flagged within the HOP database so they can be excluded from data/sample releases for research purposes. HOP has created a Data Access Committee (DAC) to review all requests for HOP data/samples. The DAC will review requests for feasibility and scientific merit before any data/samples are released. OHSU investigators wishing to receive data from this study will sign a data release agreement documenting they will: Meet all IRB requirements (IRB approval, exemption or nonhuman subjects research determination), as appropriate. Use data only for the research described in their data request and/or IRB application/ protocol and obtain additional IRB approval if secondary studies are
No publications or documents are linked to this record.
Started Mar 2020 (actual). Primary completion is estimated for Dec 2027, 93 months after the start.
Of 23 interventional studies with no phase under Hereditary Breast and Ovarian Cancer Syndrome, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31. This study's planned 93 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hereditary Breast and Ovarian Cancer Syndrome →
OHSU Knight Cancer Institute →